Nine out of ten adults in the USA struggle to understand basic health-related information. Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to understand health information. An increasing body of research in rheumatic diseases has sought to understand the impact of health literacy, long neglected as a social determinant of health, on clinical and non-clinical outcomes. Several abstracts at this year’s ACR Convergence focus on this topic.
All News
Article
Article
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases. What new data will be presented at ACR?
Article
Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
What is Osteoarthritis? A downloadable patient education page from JAMA. https://t.co/pQgGfI0boe https://t.co/pd3kygUxkH
Caoilfhionn Connolly
Tweet
🫁RP-ILD a/w high morbidity and mortality
How to Predict RP-ILD Development?
➡️AutoAb: anti-MDA5, anti-ARS, anti-Ro52
➡️Biomarkers: CRP, LD, Ferritin, KL-6
➡️CT: Lower consolidation/GGO
#ACR24 @RheumNow https://t.co/OIrHfVTZcM
Richard Conway
Tweet
Remote monitoring SHOULD increasingly be part of our care. BUT I don't think it neccessarily will. Just like with conferences reverting to non-virtual when facilitating virtual is logical from a learning perspective. There are other limiting interests in play #ACR24 @RheumNow https://t.co/UN3jGa7jVZ
David Liew
Tweet
"Do not fear RPF." - John Stone
Retroperitoneal fibrosis certainly feels challenging at times, and radiologic features might stay even after functional improvement
but we've come a long way
(although, despite B cell depletion, there's plenty more to do)
#ACR24 16S26 @RheumNow https://t.co/2Y3buXrAFY
Gabriela Martinez Zayas, MD
Tweet
Abstract 333 showed that in a cohort of patients with IIM-ILD increased age, PH, FVC decline at 1 yr, SOB at 2 years were predictors for mortality and lung transplant ! #ACR24 @RheumNow https://t.co/NgOj7WKeE3
Richard Conway
Tweet
@abdelhamed012 @RheumNow Same https://t.co/uScez6UwBp
Systematic review suggests (although not provn) that audiovestibular dysfunction may be from APS. Anti-phospholipid & HSP-70 Abs found 25-33% w/idiopathic sudden sensorineural hearing loss,. ACL Abs seen in up to 27% w/ sensorineural hearing loss https://t.co/WcmeCP0ryq https://t.co/DiYX57R0uG
Richard Conway
Tweet
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Eric Dein
Tweet
Cannabis in Pain:
CBD can help with nociceptive pain
THC better for neuropathic, centralized pain
Perhaps a role in helping decrease other medications like opiates
Clauw 16S18
#ACR24 @RheumNow https://t.co/kaQXrD4GAn
Janet Pope
Tweet
How often should #scleroderma #ILD pts have #PFTs? 🤷♂️
Data from SENCIS RCT of SSc-ILD
25% worsened FVC by 6/12
Are we UNDER a ordering PFTs in an ILD #SSc population
👇
Because if worsening we would consider a change in background #immunesuppression
@RheumNow #ACR24 #678 https://t.co/a9ybO3FwDd
Akhil Sood MD
Tweet
More steroid-sparing options for #IgG4RD!
Abstract 0775: In pts w/ IgG4:
- Inebilizumab (CD19-monoclonal ab) vs placebo associated with reduced risk of flare (HR 0.13; 95% CI 0.06, 0.28)
AEs: infections, infusion reactions, lymphopenia
#ACR24 @RheumNow https://t.co/Vr5hcd2E7E
Bella Mehta
Tweet
Researchers developed a digital messaging program to reduce fatigue in SLE
- Grounded in social cognitive and self-determination theories
- Reviewed 148 messages, refined based on patient feedback
- High patient ratings, future will see more of these #ACR24 abst#0362 @RheumNow
Eric Dein
Tweet
Ab#0427 #ACR24
HSS: menopause & systemic rheum disease severity
1/3 women report worse disease associated w menopause
Reported more flares, menopausal symptoms
Findings were similar between SLE and RA, but SLE patients were >2x more likely to discuss w their rheum
@RheumNow
Bella Mehta
Tweet
Nationwide US study
-Prevalence of HLH in SLE: 0.13%
-Higher risk in younger, female, and racial minority patients
- Strong association with high mortality #ACR24 abst#0619 @RheumNow
Bella Mehta
Tweet
Study on #AI-augmented remote care for SLE:
- Combined biometric, self-reported, and NLP-extracted data
- Moderate to strong correlations with physician global assessment
- Potential to improve remote disease management - but now very accurate for now
#ACR24 abst#0635 @RheumNow
Gabriela Martinez Zayas, MD
Tweet
This abstract reports that patients with ESRD 2/2 to GPA have a higher risk of vertebral fractures compared to individuals with ESRD without GPA. Even low dose steroids (pred 5mg) taken during the first year of HD conferred an increase risk or facture! #ACR24 @RheumNow https://t.co/4xM3XTCHSH
Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate
All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission
#ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO
